These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30623356)

  • 1. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Tobinai K; Uchida T; Fukuhara N; Nishikawa T
    Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
    J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 5. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
    Ruella M; Soubeyran P
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
    Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
    Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
    Xu L; Shadman M; Flinn IW; Levy MY; Porter R; Burke JM; Zafar SF; Cultrera JL; Misleh J; Kingsley EC; Yimer HA; Freeman B; Chaudhry A; Tumula PK; Gandhi MD; Crescenzo R; By K; Cohen A; Chen DY; Idoine A; Manda S; Sharman JP; Ramakrishnan V
    Haematologica; 2024 Jul; 109(7):2284-2289. PubMed ID: 38268449
    [No Abstract]   [Full Text] [Related]  

  • 9. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Lee CS; Rattu MA; Kim SS
    J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
    Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
    McMullen JR; Boey EJ; Ooi JY; Seymour JF; Keating MJ; Tam CS
    Blood; 2014 Dec; 124(25):3829-30. PubMed ID: 25498454
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    Ball S; Vutthikraivit W; Maiti A; Short NJ
    Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
    [No Abstract]   [Full Text] [Related]  

  • 15. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
    Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
    Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
    Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
    Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Rule S; Jurczak W; Jerkeman M; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Thieblemont C; Zhou W; Henninger T; Goldberg J; Vermeulen J; Dreyling M
    Leukemia; 2018 Aug; 32(8):1799-1803. PubMed ID: 29572505
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
    Zhou Y; Lu H; Yang M; Xu C
    Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    Babbili A; Lakra R; Thotamgari SR; Gaddam SJ; Grewal US; Dominic P
    Am J Ther; 2024 Jul-Aug 01; 31(4):e453-e455. PubMed ID: 38305826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.